{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T21:01:14Z","timestamp":1780261274143,"version":"3.54.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcf.2026.05.007","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:16:53Z","timestamp":1779311813000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of discontinuation and reduction of respiratory cotherapies on the effectiveness of CFTR modulators"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7055-053X","authenticated-orcid":false,"given":"Q.","family":"Reynaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Payet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7013-0613","authenticated-orcid":false,"given":"V.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bessou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9478-5464","authenticated-orcid":false,"given":"M.","family":"Belhassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Durieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-1970","authenticated-orcid":false,"given":"M.","family":"Viprey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2026.05.007_bib0001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"21","key":"10.1016\/j.jcf.2026.05.007_bib0002","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcf.2026.05.007_bib0003","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"19","key":"10.1016\/j.jcf.2026.05.007_bib0004","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.007_bib0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2026.05.007_bib0006","article-title":"Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir Med Res"},{"key":"10.1016\/j.jcf.2026.05.007_bib0007","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcf.2017.07.001","article-title":"Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting","volume":"17","author":"Hubert","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2026.05.007_bib0008","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic effects of elexacaftor-tezacaftor-ivacaftor in adults with cystic fibrosis and advanced lung disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann Am Thorac Soc"},{"issue":"7","key":"10.1016\/j.jcf.2026.05.007_bib0009","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/ppul.27018","article-title":"Medication utilization and lung function changes after initiation of treatment with elexacaftor\/tezacaftor\/ivacaftor","volume":"59","author":"De Vuyst","year":"2024","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.007_bib0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jcf.2024.11.004","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on utilization of routine therapies in cystic fibrosis: Danish nationwide register study","volume":"24","author":"R\u00e5ket","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.007_bib0013","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jcf.2021.03.025","article-title":"Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis","volume":"21","author":"Durieu","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.007_bib0014","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jcf.2024.03.001","article-title":"Health care resource utilization preceding death or lung transplantation in people with cystic fibrosis: HCRU before transplant or death in cystic fibrosis","volume":"23","author":"Guyot","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.05.007_bib0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997\u20132001: variations with spatial scale, degree of urbanicity, age, gender and cause of death","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.007_bib0016","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"issue":"2","key":"10.1016\/j.jcf.2026.05.007_bib0017","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"issue":"25","key":"10.1016\/j.jcf.2026.05.007_bib0018","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.jcf.2026.05.007_bib0019","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jcf.2019.11.007","article-title":"Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy","volume":"19","author":"Gifford","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.05.007_bib0020","article-title":"Elexacaftor\/tezacaftor\/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis","author":"Sagel","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.007_bib0021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2023.05.001","article-title":"Use of cystic fibrosis inhaled medication before and after elexacaftor\/tezacaftor\/ivacaftor initiation","volume":"23","author":"Manika","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.05.007_bib0022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12931-024-03089-2","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis","volume":"26","author":"Gramegna","year":"2025","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.jcf.2026.05.007_bib0023","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2026.05.007_bib0024","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1513\/AnnalsATS.202507-817OC","article-title":"Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"23","author":"Sagel","year":"2026","journal-title":"Ann Am Thorac Soc."},{"issue":"2","key":"10.1016\/j.jcf.2026.05.007_bib0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2026.05.007_bib0026","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2019.09.018","article-title":"Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France","volume":"19","author":"Olivereau","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.05.007_bib0027","article-title":"Using chest computed tomography and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis","volume":"59","author":"Campredon","year":"2022","journal-title":"Eur Respir J"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932600113X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932600113X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T20:06:29Z","timestamp":1780257989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932600113X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"alternative-id":["S156919932600113X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of discontinuation and reduction of respiratory cotherapies on the effectiveness of CFTR modulators","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}